8.09
price up icon6.73%   0.51
after-market アフターアワーズ: 8.11 0.02 +0.25%
loading
前日終値:
$7.58
開ける:
$7.79
24時間の取引高:
7.20M
Relative Volume:
1.81
時価総額:
$711.62M
収益:
$45.97M
当期純損益:
$-508.80M
株価収益率:
-1.4763
EPS:
-5.48
ネットキャッシュフロー:
$-382.65M
1週間 パフォーマンス:
+17.76%
1か月 パフォーマンス:
+11.59%
6か月 パフォーマンス:
-45.04%
1年 パフォーマンス:
-64.75%
1日の値動き範囲:
Value
$7.75
$8.40
1週間の範囲:
Value
$6.9175
$8.40
52週間の値動き範囲:
Value
$5.90
$28.18

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1170)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
598
Name
Twitter
@intelliatweets
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

NTLA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NTLA
Intellia Therapeutics Inc
8.09 711.62M 45.97M -508.80M -382.65M -5.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Jun 06, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus

Jun 06, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView

Jun 04, 2025
pulisher
Jun 03, 2025

(NTLA) Investment Report - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus

Jun 03, 2025
pulisher
May 31, 2025

ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus

May 31, 2025
pulisher
May 30, 2025

Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga

May 30, 2025
pulisher
May 30, 2025

ARK Investment Acquires 226K Shares of Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria

May 30, 2025
pulisher
May 30, 2025

Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com Australia

May 30, 2025
pulisher
May 30, 2025

Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN

May 30, 2025
pulisher
May 30, 2025

StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity - Genetic Engineering and Biotechnology News

May 30, 2025
pulisher
May 30, 2025

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance

May 30, 2025
pulisher
May 30, 2025

Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN

May 30, 2025
pulisher
May 30, 2025

Intellia shares tumble on safety signal in gene-editing trial - The Pharma Letter

May 30, 2025
pulisher
May 30, 2025

Intellia stock dips following safety event in Phase III gene therapy trial - Clinical Trials Arena

May 30, 2025
pulisher
May 30, 2025

Intellia Therapeutics (NTLA) Receives Continued 'Buy' Rating fro - GuruFocus

May 30, 2025
pulisher
May 29, 2025

Intellia: Shares Sink on Safety Concern in Phase 3 Trial; Lowering Fair Value to $60 From $75 - Morningstar

May 29, 2025
pulisher
May 29, 2025

ARK Investment Acquires Significant Stake in Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

No-Moat Intellia's Gene-Editing Pipeline Looks Promising for Long-Term, Risk-Tolerant Investors - Morningstar

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concer - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Stu - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia adverse event could resurface questions, says JPMorgan - TipRanks

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Setback with Late-Stage Trial Incident - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia: Heart Disease Safety Setback Triggers SelloffCaution Advised (NASDAQ:NTLA) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Intellia Shares Drop 19% After Safety Signal Emerges in Phase 3 Trial - MSN

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics Shares Drop 25 Percent After Liver Stress Reported in Gene-Editing Trial - geneonline.com

May 29, 2025
pulisher
May 29, 2025

Intellia tumbles on liver safety signal for CRISPR therapy - FirstWord Pharma

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating - TipRanks

May 29, 2025
pulisher
May 29, 2025

Intellia filing spurs safety concerns over CRISPR drug - BioPharma Dive

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga

May 29, 2025
pulisher
May 29, 2025

Intellia commercial position in question after safety event. says Goldman - TipRanks

May 29, 2025
pulisher
May 29, 2025

Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concerns | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue - BioSpace

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Study Concerns | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia stock holds $45 target despite AE concerns By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 29, 2025

Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith - Fierce Biotech

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Stock Drops After Trial Update | NT - GuruFocus

May 29, 2025
pulisher
May 29, 2025

H.C. Wainwright maintains $30 target on Intellia stock post-safety update - Investing.com

May 29, 2025
pulisher
May 29, 2025

Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews - Benzinga

May 29, 2025
pulisher
May 29, 2025

Cantor maintains Intellia stock at $65 target despite trial concern By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Intellia stock tumbles on safety concerns By Investing.com - Investing.com Canada

May 29, 2025
pulisher
May 29, 2025

Intellia stock tumbles on safety concerns - Investing.com

May 29, 2025
pulisher
May 29, 2025

Intellia stock down on safety concern for gene editing drug - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating - marketscreener.com

May 29, 2025

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
大文字化:     |  ボリューム (24 時間):